Abstract |
Gorlin-Goltz syndrome, also referred to as naevoid basal cell carcinoma syndrome ( NBCCS), is an autosomal dominant skin disease with complete penetrance and inconstancy of the four major findings: multiple naevoid basal cell carcinomas (BCCs), pits on palms and soles, skeletal abnormalities (for example, jaw cysts), and ectopic calcification. The treatment of multiple BCCs is still a matter of debate. We report three cases of multiple BCCs in Gorlin-Goltz syndrome treated with topical 5% imiquimod cream, an immune response modifier. Patients were successfully cleared of BCCs after treatment for 6-8 weeks. Histologically no apparent signs of BCC-persistence could be detected and no recurrences were detected during the 12 month follow up period.
|
Authors | Eggert Stockfleth, Claas Ulrich, Axel Hauschild, Stephan Lischner, Thomas Meyer, Enno Christophers |
Journal | European journal of dermatology : EJD
(Eur J Dermatol)
2002 Nov-Dec
Vol. 12
Issue 6
Pg. 569-72
ISSN: 1167-1122 [Print] France |
PMID | 12459530
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Aminoquinolines
- Imiquimod
|
Topics |
- Administration, Topical
- Adult
- Aged
- Aminoquinolines
(administration & dosage)
- Basal Cell Nevus Syndrome
(drug therapy, pathology)
- Biopsy, Needle
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Face
- Female
- Follow-Up Studies
- Humans
- Imiquimod
- Immunohistochemistry
- Male
- Middle Aged
- Sampling Studies
- Skin Neoplasms
(drug therapy, pathology)
- Treatment Outcome
|